PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32381576-8	2021	Given that NF-kappaB plays a role in both bortezomib and ibrutinib resistance mechanisms, these data provide a strong rationale for the use of DC-1-192 in the treatment of NF-kappaB-driven cancers, particularly in the context of relapsed/refractory disease.	ibrutinib	57-66	nuclear factor kappa B subunit 1	Homo sapiens	11-20